Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study

Pascale Palassin (1) , Alexandre Maria (2, 1) , Chayma Ladhari (1) , Xavier Quantin (3) , David Montani (4, 5) , Arnaud Bourdin (6, 1) , Clément Boissin (1) , Pierre Fesler (6, 1) , Dominique Hillaire-Buys (1) , Philippe Guilpain (2, 1) , Jean-Luc Faillie (7, 1)

1 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
2 Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB)
3 ICM - Institut régional de Cancérologie de Montpellier
4 Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
5 Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
6 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
7 IDESP - Institut Desbrest de santé publique

Immune checkpoint inhibitors (ICI) restore immune response against cancer cells that can lead to immune-related adverse effects. While cardiovascular immune-related adverse effects are known to be associated with checkpoint inhibitors, recent case reports have raised concerns about the potential association with pulmonary hypertension (PH). By using the global pharmacovigilance database VigiBase, we investigated the onset of PH associated with ICI and propose a comprehensive description of the 42 cases of PH reported with ICI recorded in this database. Through this study and review of the cases published in the literature, we discuss the possible link between PH and ICI in the context of cancer in order to better understand this rare but potentially fatal event

Mots clés: Pulmonary hypertension; Immune checkpoint inhibitors; Pharmacovigilance; Auto-immune disorders; Adverse drug reactions

Domaines: Cancer; Immunothérapie; Cardiologie et système cardiovasculaire; Santé publique et épidémiologie

Pascale Palassin, Alexandre Maria, Chayma Ladhari, Xavier Quantin, David Montani, et al.. Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study. Cancer Immunology, Immunotherapy, 2022, 71 (12), pp.3093-3097. ⟨10.1007/s00262-022-03208-2⟩. ⟨hal-03680007⟩